[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shengjing Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":601},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,46,0,25,[9,46,74,107,131,155,172,198,222,251,275,300,319,341,363,388,410,430,452,476,499,516,541,562,579],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100644637","effect-of-cerebellar-fastigial-nucleus-stimulation-combined-with-sling-exercise-on-motor-function-in-hemiplegic-stroke-patients-100644637",false,"NCT07670936","Effect of Cerebellar Fastigial Nucleus Stimulation Combined With Sling Exercise on Motor Function in Hemiplegic Stroke Patients","Effects of Cerebellar Fastigial Nucleus Electrical Stimulation Combined With Sling Exercise Therapy on Motor Function in Hemiplegic Patients After Stroke","Inclusion Criteria:\n\n1. Met the diagnostic criteria for cerebrovascular disease in Western medicine;\n2. Were conscious, with stable vital signs and emotional state;\n3. Were male or female, aged 18 to 70 years, with disease onset within the previous 6 months;\n4. Had no significant cognitive or auditory comprehension impairments, were able to understand and execute relevant instructions, and could cooperate with the completion of relevant rehabilitation assessments;\n5. Were informed about the study and had signed an informed consent form.\n\nExclusion Criteria:\n\n1. Presence of severe organ dysfunction involving the cardiovascular, pulmonary, liver, or renal systems;\n2. Severe joint diseases, incompletely healed fractures, or severe osteoporosis;\n3. History of psychiatric illness or severe cognitive, visual, or auditory comprehension impairments that would prevent cooperation with instructions;\n4. Concurrent vestibular dysfunction;\n5. Unstable vital signs;\n6. Patients requiring mechanical ventilation;\n7. Contraindications to FNS, such as a history of epilepsy or the presence of intracranial metal foreign bodies.","ALL","18 Years","70 Years",{"count":21,"type":22},54,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to investigate the rehabilitative effects and synergistic potential of combining Fastigial Nucleus Stimulation (FNS) with Sling Exercise Training (SET) on motor function in patients with post-stroke hemiplegia. Hemiplegia after stroke often results in unilateral motor impairment, balance dysfunction, and decreased proprioception. Although traditional rehabilitation methods can improve certain functions, they are often limited by insufficient central targeting and inadequate activation of deep core muscles, making it difficult to fundamentally repair damaged motor control circuits. FNS, as a non-invasive neuromodulation technique, can precisely target the fastigial nucleus-a critical hub for motor coordination and balance control-thereby modulating neuroplasticity and promoting regional cerebral blood flow to optimize cortical function. SET, on the other hand, utilizes an unstable sling system to efficiently activate deep core muscles (such as the transversus abdominis and multifidus), enhance proprioceptive input, and promote neural reorganization. Based on the concept of \"central regulation-peripheral enhancement,\" this study hypothesizes that the combination of FNS and SET can create a bidirectional intervention pathway, breaking the vicious cycle between central damage and peripheral dysfunction, and achieving a \"1+1\\>2\" therapeutic effect. This study employs a randomized, double-blind, sham-controlled design and plans to enroll 54 eligible patients with post-stroke hemiplegia (aged 18-70 years, within 6 months of onset). Participants will be randomly assigned to three groups: Group A (FNS + sham SET), Group B (sham FNS + SET), and Group C (FNS + SET). FNS will be delivered using high-precision electrodes placed over the bilateral mastoid regions, with a stimulation frequency of 180 Hz and an intensity of 2 mA (sham stimulation at 0.1 mA) for 20 minutes per session. SET will include supine and prone bridging exercises for 30 minutes per session, while sham SET involves suspension without active movement. All patients will be assessed before and after the intervention using the Berg Balance Scale, Fugl-Meyer Assessment, three-dimensional gait analysis, trunk control test, and proprioceptive measurement instruments. The sample size was calculated based on previous data for lower extremity Fugl-Meyer scores (effect size f = 0.502), with an estimated 20% dropout rate, resulting in a target of 54 participants. The innovation of this study lies in its first-time combination of FNS-a more targeted neuromodulation approach-with SET-a high-intensity sensorimotor integration training-and the use of sham controls to precisely quantify the individual contributions of each intervention and validate the synergistic effect of central-peripheral co-stimulation. Potential risks will be strictly managed: FNS may cause localized tingling or mild headache, which can be addressed by adjusting or pausing stimulation; SET will be conducted under the supervision of trained therapists with individualized intensity adjustments to prevent muscle soreness or falls. All adverse events will be documented and managed promptly. The findings of this study are expected to provide an effective, non-invasive central-peripheral synergistic rehabilitation strategy for post-stroke hemiplegia and offer evidence-based guidance for clinical practice and future research.",[28],"Stroke",[28,30,31,32,33],"Cerebellar Fastigial Nucleus Electrical Stimulation","Sling Exercise Therapy","Three-Dimensional Gait","Motor Function","NOT_YET_RECRUITING","2026-07-01",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":35,"type":22},{"date":41,"type":22},"2027-04-30",{"name":43,"class":44},"Shengjing Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100550883","multimodal-magnetic-resonance-imaging-in-evaluation-of-diabetic-kidney-disease-100550883","NCT06452862","Multimodal Magnetic Resonance Imaging in Evaluation of Diabetic Kidney Disease","the Value of Multimodal Magnetic Resonance Imaging in the Diagnosis and Treatment Monitoring of Diabetic Kidney Disease","Inclusion Criteria:\n\n* Clinically diagnosed diabetic kidney disease (DKD)\n* Age 18-80 years\n\nExclusion Criteria:\n\n* Malignant tumor, active infection, or life expectancy \\\u003C1 year\n* Pregnancy or lactation\n* MRE contraindications (metal implants, claustrophobia, severe arrhythmia) or poor image quality\n* eGFR \\\u003C15 mL\u002Fmin\u002F1.73m² or receiving renal replacement therapy\n* Other primary kidney diseases or systemic diseases affecting renal function",true,"80 Years",{"count":56,"type":22},150,"OBSERVATIONAL","The goal of this study is to investigate the value of noninvasive evaluation of multimodal magnetic resonance imaging in diagnosis and treatment of diabetic kidney disease (DKD). We aim to explore the feasibility of multimodal magnetic resonance imaging in the staging diagnosis of DKD, and establish a non-invasive method for evaluating the progression of DKD disease by combining imaging and biochemical indicators. Multimodal magnetic resonance examinations will be performed on diabetic patients with different stages as well as regular follow-up during treatment, in order to investigate the relationship between imaging findings and pathophysiological changes of the kidneys.",[60],"Diabetic Kidney Disease",[60,62,63,64],"Magnetic Resonance Imaging","Magnetic Resonance Elastography","Diabetes","RECRUITING","2026-04-06",{"date":68,"type":38},"2026-04-13",{"date":70,"type":38},"2024-06-06",{"date":72,"type":22},"2028-06-06",{"name":43,"class":44},{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":86,"studyType":57,"phases":4,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100631170","amh-dynamic-changes-to-predict-ovarian-reserve-in-perimenopausal-breast-cancer-100631170","NCT07497191","AMH Dynamic Changes to Predict Ovarian Reserve in Perimenopausal Breast Cancer","A Clinical Model Based on Dynamic Changes in Anti-Müllerian Hormone to Predict Ovarian Reserve in Perimenopausal Breast Cancer Patients","Inclusion Criteria:\n\n1. Female, aged 45-55 years\n2. Histologically confirmed hormone receptor-positive breast cancer\n3. Perimenopausal status defined as: (a) last menstrual period within 3 months prior to enrollment; and (b) FSH 10-40 IU\u002FL and E2 \\>20 pg\u002FmL\n4. Scheduled to receive adjuvant chemotherapy and\u002For endocrine therapy\n5. Willing to undergo serial blood sampling and complete menstrual diaries\n6. Able to provide written informed consent\n\nExclusion Criteria:\n\n1. Postmenopausal status\n2. Prior bilateral oophorectomy or pelvic radiotherapy\n3. Severe hepatic or renal dysfunction\n4. Estrogen receptor (ER)-negative and progesterone receptor (PR)-negative breast cancer\n5. Conditions affecting ovarian hormone secretion (e.g., ovarian tumors, polycystic ovary syndrome, pituitary tumors)\n6. Current pregnancy, lactation, or planned pregnancy during follow-up\n7. Use of hormonal intrauterine devices\n8. Prior use of GnRH agonists or aromatase inhibitors","FEMALE","45 Years","55 Years",{"count":85,"type":22},300,"3 Years","This study is a prospective observational cohort study aimed at developing a clinical model based on dynamic changes in anti-Müllerian hormone (AMH) to predict ovarian reserve in perimenopausal women with hormone receptor-positive breast cancer.\n\nThe study will enroll approximately 300 women aged 45-55 years with perimenopausal status confirmed by menstrual history and hormone levels (FSH 10-40 IU\u002FL, E2 \\>20 pg\u002FmL). Participants will be stratified by treatment regimen: (A) chemotherapy plus endocrine therapy, (B) chemotherapy plus targeted therapy plus endocrine therapy, and (C) endocrine therapy alone.\n\nBlood samples will be collected at seven time points to measure AMH, FSH, E2, and LH. Menstrual patterns and menopausal symptoms will be recorded prospectively. The primary outcome is the association between dynamic AMH changes and the occurrence of menopause. A predictive model will be constructed using LASSO regression and Cox proportional hazards models, with internal validation by bootstrap resampling.\n\nThe goal is to develop a clinically applicable tool to guide endocrine therapy decisions-including the duration of ovarian function suppression (OFS), choice between tamoxifen and aromatase inhibitors (AIs), and selection of CDK4\u002F6 inhibitors-as well as to provide individualized fertility preservation counseling for perimenopausal breast cancer patients.",[89,90,91],"Breast Cancer","Perimenopause","Ovarian Reserve",[93,91,94,95,96,97,98],"Anti-Müllerian Hormone","Perimenopausal Breast Cancer","Dynamic Monitoring","Predictive Model","Endocrine Therapy","Chemotherapy-Induced Amenorrhea","2026-03-23",{"date":101,"type":38},"2026-03-27",{"date":103,"type":22},"2026-03-05",{"date":105,"type":22},"2030-03-05",{"name":43,"class":44},{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":81,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":4},"100630214","predicting-recurrence-in-hrher2--early-breast-cancer-100630214","NCT07484763","Predicting Recurrence in HR+\u002FHER2- Early Breast Cancer","A Single-Center Retrospective Study to Develop a Nomogram for Predicting Recurrence in HR+\u002FHER2- Early Breast Cancer Using Real-World Data","Inclusion Criteria:\n\n* Histopathologically confirmed invasive breast ductal carcinoma or lobular carcinoma;\n* Molecular subtype of HR+\u002FHER2- (ER ≥ 10%, and HER2 immunohistochemistry 0\u002F1+ or 2+ without amplification confirmed by FISH);\n* Received standardized surgical treatment and postoperative adjuvant (or preoperative neoadjuvant) endocrine therapy;\n* Complete follow-up data available.\n\nExclusion Criteria:\n\n* Presence of distant metastasis (Stage IV) at diagnosis\n* Male breast cancer\n* Missing key clinicopathological data or loss to follow-up\n* HER2 immunohistochemistry 3+ or 2+ with amplification confirmed by FISH\n* Triple-negative breast cancer",{"count":115,"type":22},500,"Hormone receptor-positive\u002Fhuman epidermal growth factor receptor 2-negative (HR+\u002FHER2-) breast cancer constitutes approximately 70% of all breast cancer cases. Although early-stage patients generally have favorable outcomes following standard surgery and adjuvant endocrine therapy, long-term follow-up data reveal a distinct \"bimodal\" or \"long-tail\" recurrence pattern, with risks persisting for decades. Recent landmark trials (e.g., NATALEE, MonarchE) have established that combining CDK4\u002F6 inhibitors with endocrine therapy significantly improves invasive disease-free survival (iDFS) in high-risk populations. However, the stringent enrollment criteria of these randomized controlled trials may not fully capture the heterogeneity of real-world patients. Reliance on binary cut-off values (e.g., nodal status alone) risks misclassifying biologically high-risk individuals with low anatomical burden, leading to either undertreatment or overtreatment. There is an urgent clinical need for a multidimensional, individualized risk assessment tool to guide escalated therapy decisions.",[118],"Breast Cancer, HR+\u002FHER2- Early-Stage",[89,120,121,122],"HR+\u002FHER2-","Nomogram","Recurrence","2026-03-16",{"date":125,"type":38},"2026-03-20",{"date":127,"type":22},"2026-04-01",{"date":129,"type":22},"2027-04-01",{"name":43,"class":44},{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":141,"conditions":142,"keywords":146,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":45},"100476310","adverse-outcome-of-acute-pulmonary-embolism-by-artificial-intelligence-system-based-on-ct-pulmonary-angiography-100476310","NCT05482269","Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography","Prediction of Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography","PEAICTPA","Inclusion Criteria:\n\n* age of ≥ 18 years and a pulmonary embolism diagnosis based on CT pulmonary angiography\n\nExclusion Criteria:\n\n* pregnancy\n* reception of reperfusion treatment before admission\n* missing data regarding CT parameters, echocardiography, cardiac troponin I (c-Tn I), and N-terminal-pro brain natriuretic peptide (NT-pro BNP) levels.",{"count":140,"type":22},2000,"The investigators aim to build a predictive tool for Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography.",[143,144,145],"Pulmonary Embolism and Thrombosis","Deterioration, Clinical","Artificial Intelligence",[143,144,145],"2026-03-08",{"date":149,"type":38},"2026-03-11",{"date":151,"type":38},"2011-01-01",{"date":153,"type":22},"2026-12-31",{"name":43,"class":44},{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":162,"targetDuration":163,"studyType":57,"phases":4,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":171,"locationsCount":45},"100446848","a-predictive-tool-for-predicting-adverse-outcomes-in-acute-pulmonary-embolism-patients-using-ctpa-100446848","NCT05098769","A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA.","A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using Parameters Obtained by Computed Tomographic Pulmonary Angiography.","Inclusion Criteria:\n\n* age of ≥ 18 years and a PE diagnosis based on CT pulmonary angiography\n\nExclusion Criteria:\n\n* pregnancy\n* reception of reperfusion treatment before admission\n* missing data regarding CT parameters, echocardiography, cardiac troponin I (c-Tn I), and N-terminal-pro brain natriuretic peptide (NT-pro BNP) levels.",{"count":85,"type":22},"30 Days","This study collected clinical, laboratory, and CT parameters of acute patients with acute pulmonary embolism from admission to predict adverse outcomes within 30 days after admission into hospital.",[143,144],[143,144],{"date":149,"type":38},{"date":169,"type":38},"2021-01-18",{"date":153,"type":22},{"name":43,"class":44},{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":179,"targetDuration":181,"studyType":57,"phases":4,"briefSummary":182,"conditions":183,"keywords":186,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":45},"100575959","mr-elastography-for-assessing-liver-fibrosis-in-chronic-hepatitis-b-100575959","NCT06779058","MR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B","Retrospective and Prospective Multi-center Clinical Study of Magnetic Resonance Elastography in Evaluating Hepatic Fibrosis in Chronic Viral Hepatitis B","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Confirmed CHB (laboratory, imaging and clinical tests)\n* MRE within 6 months before and after liver biopsy\n* Treatment-naïve\n* Child-Pugh Grade A (\\\u003C7 points)\n* Written informed consent in prospective follow-up cohort\n\nExclusion Criteria:\n\n* Patients with liver malignant tumor\n* Chronic hepatitis due to other causes (such as alcoholic hepatitis)\n* CHB combined with hepatitis C, hepatitis D, or HIV\n* Patients with biliary tract diseases\n* Contraindications of MRE examination, MRE failure\n* Poor pathological effect",{"count":180,"type":22},600,"2 Years","How to construct a non-invasive, accurate, and convenient method to evaluate the severity of liver fibrosis (LF) is an important general problem in the management of patients with chronic hepatitis B (CHB). We plan to investigate the ability of magnetic resonance elastography (MRE) to grade fibrosis in chronic hepatitis B and apply to clinical longitudinal follow-up.",[184,185],"Chronic Hepatitis B","Liver Fibrosis",[187,188,189],"Magnetic resonance elastography","Liver stiffness","Antiviral therapy","2026-02-26",{"date":192,"type":38},"2026-02-27",{"date":194,"type":38},"2025-01-01",{"date":196,"type":22},"2026-12-01",{"name":43,"class":44},{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":205,"targetDuration":4,"studyType":23,"phases":206,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":45},"100589499","3d-mre-based-evaluation-of-meningioma-mechanical-properties-and-histological-features-100589499","NCT06955208","3D MRE-Based Evaluation of Meningioma Mechanical Properties and Histological Features","Evaluation of Meningioma Mechanical Properties and Histological Features Using Three-Dimensional Magnetic Resonance Elastography","Inclusion Criteria:\n\n* All patients undergoing meningeoma resection surgery are eligible for inclusion in the study cohort.\n\nExclusion Criteria:\n\n* Patients with metallic implants or foreign bodies in their bodies (pacemakers, artificial metallic heart valves, metal joints, metal implants, and those who can not remove dentures, insulin pumps, or contraceptive rings)\n* Pregnant women in the first trimester (within three months)\n* Patients with severe claustrophobia or anxiety\n* Patients with severe fever\n* Patients who can not tolerate MRE\n* Patients with vascular malformations and aneurysms.\n* Patients who do not sign an informed consent",{"count":85,"type":22},[25],"This prospective single-center study aims to evaluate the feasibility and clinical utility of three-dimensional magnetic resonance elastography (3D MRE) in assessing tumor stiffness and adhesion in patients with meningioma undergoing surgical resection. By correlating preoperative MRE-derived stiffness and adhesion maps with intraoperative findings and histopathological features, the study seeks to determine whether MRE can serve as a noninvasive imaging biomarker for surgical planning, risk stratification, and prediction of tumor behavior.",[209],"Meningioma",[187,209,211,212,213],"Stiffness","Adhesion","Neurosurgery","2026-02-10",{"date":216,"type":38},"2026-02-12",{"date":218,"type":38},"2022-10-19",{"date":220,"type":22},"2027-10-09",{"name":43,"class":44},{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":229,"targetDuration":4,"studyType":23,"phases":231,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":45},"100512840","mre-evaluation-for-spinal-cord-tumor-surgery-stiffness-and-adhesion-assessment-100512840","NCT05957679","MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion Assessment","Preoperative Evaluation of Tumor Stiffness and Adhesion in Spinal Cord Tumor Using Magnetic Resonance Elastography","Inclusion Criteria:\n\n* All patients undergoing spinal cord tumor resection surgery are eligible for inclusion in the study cohort.\n\nExclusion Criteria:\n\n* Patients with metallic implants or foreign bodies in their bodies (pacemakers, artificial metallic heart valves, metal joints, metal implants, and those who cannot remove dentures, insulin pumps, or contraceptive rings)\n* Pregnant women in the first trimester (within three months)\n* Patients with severe claustrophobia or anxiety\n* Patients with severe fever\n* Patients who can not tolerate MRE\n* Patients with vascular malformations and aneurysms.\n* Patients who do not sign an informed consent",{"count":230,"type":22},20,[25],"In spinal cord tumors requiring surgical intervention, the resection difficulty is determined by two significant factors: tumor stiffness and adhesion to surrounding tissue.\n\nThe stiffness of the tumor dictates the complexity of removal, while strong adhesion presents additional challenges during the surgical procedure.\n\nThis clinical trial aims to assess the clinical utility of magnetic resonance elastography (MRE), in evaluating the stiffness and adhesion of spinal cord tumors and guiding surgical planning to selecting the most appropriate surgical approach for patients with spinal cord tumors.",[234],"Spinal Cord Tumors",[236,237,238,63,239,240,241,242,243,244],"MRE","Slip Interface Imaging","Glioma","Spinal meningioma","Neurofibroma","Ependymoma","Astrocytoma","Glioblastoma","Spinal lipoma",{"date":216,"type":38},{"date":247,"type":38},"2023-01-01",{"date":249,"type":22},"2027-09-01",{"name":43,"class":44},{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":45},"100531625","multifrequency-mre-in-evaluation-of-chronic-kidney-diseases-100531625","NCT06202235","Multifrequency MRE in Evaluation of Chronic Kidney Diseases","Multifrequency Renal MR Elastography in Evaluation of Chronic Kidney Diseases: Can Shear Stiffness Evaluate Renal Fibrosis in GFR-normal Patients?","Inclusion Criteria:\n\n(1) adults with CKD defined according to the 2024 KDIGO guidelines, with either elevated SCr or abnormal proteinuria ; and (2) renal MRI was performed within 7 days of the renal biopsy.\n\nExclusion criteria:\n\n(1) genitourinary malignancy, polycystic kidney disease, renal transplantation, or acute renal failure; (2) contraindications for MRI examination; (3) poor image quality; (4) kidney deformity or severe hydronephrosis on MRI; and (5) poorly defined corticomedullary demarcation.","65 Years",{"count":260,"type":22},200,"Chronic Kidney Disease (CKD) is a major public health issue, leading to high mortality and the necessity for renal replacement therapy. Kidney fibrosis, resulting from chronic damage to kidney tissue, significantly determines CKD outcomes. Kidney biopsy, the gold standard for assessing fibrosis, is invasive and limited in its ability to reflect the heterogeneous nature of fibrosis. Consequently, there is growing interest in noninvasive methods, particularly Magnetic Resonance Elastography (MRE). MRE, which evaluates tissue stiffness, has shown potential for assessing kidney fibrosis. This study aims to use multifrequency MRE to assess renal fibrosis, focusing particularly on the early stages of CKD, to enhance understanding of its progression and relationship to clinical outcomes.",[263],"Chronic Kidney Disease (CKD)",[265,266,267],"chronic kidney disease","kidney fibrosis","MR elastography","2026-02-07",{"date":214,"type":38},{"date":271,"type":38},"2022-10-10",{"date":273,"type":22},"2027-06-08",{"name":43,"class":44},{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":285,"conditions":286,"keywords":289,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":299,"locationsCount":45},"100531914","3d-mre-and-2d-mre-for-assessing-cirrhosis-and-portal-hypertension-100531914","NCT06205992","3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension","Three-dimensional MR Elastography and Two-dimensional MR Elastography for Assessing Cirrhosis and Portal Hypertension：A Prospective Multicenter Study","Inclusion Criteria:\n\n1. age \\> 18 years old\n2. confirmed cirrhosis (laboratory, imaging and clinical symptoms)\n3. with 3D-MRE and 2D-MRE within 1 month prior to HVPG measurement\n4. written informed consent\n\nExclusion Criteria:\n\n1. any previous liver or spleen surgery\n2. liver cancer; chronic acute liver failure\n3. acute portal hypertension\n4. unreliable HVPG, 3D-MRE or 2D-MRE results due to technical reasons\n5. with liver interventional therapy between HVPG and MRE","75 Years",{"count":284,"type":22},100,"How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis. We plan to compare the ability of three demensional-magnetic resonance elastography (3D-MRE) to two demensional-magnetic resonance elastography (2D-MRE) to establish a risk stratification system and perform tailored management for portal hypertension in cirrhosis.",[287,288],"Cirrhosis","Liver Portal Hypertension",[290,291,292],"3D-MRE","2D-MRE","HVPG","2026-02-05",{"date":295,"type":38},"2026-02-09",{"date":297,"type":38},"2022-08-16",{"date":196,"type":22},{"name":43,"class":44},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":282,"enrollmentInfo":307,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":308,"conditions":309,"keywords":313,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":317,"leadSponsor":318,"locationsCount":45},"100475752","3d-mre-for-assessing-cirrhosis-advanced-chronic-liver-disease-and-portal-hypertension-100475752","NCT05475015","3D-MRE for Assessing Cirrhosis, Advanced Chronic Liver Disease and Portal Hypertension","Three-dimensional MR Elastography for Assessing Cirrhosis and Portal Hypertension (CHESS2206): A Prospective Multicenter Study","Inclusion criteria were: (1) ≥18 years; (2) written informed consent; (3) confirmed ACLD of any liver disease etiology; (4) clinically indicated for HVPG measurement, with 3D-MRE performed within one month prior.\n\nExclusion criteria were: (1) hepatic or extrahepatic malignancies, or large hepatic or splenic focal diseases affecting MRE measurement; (2) MR or HVPG contraindications; (3) prior liver or splenic surgery affecting MRE measurement; (4) treatment with nonselective β-blockers (NSBB) between MRE and HVPG measurements; (5) invalid or unreliable HVPG or MRE results and (6) biliary obstruction or dilation on MR images.",{"count":56,"type":22},"How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis or advanced chronic liver disease. We plan to investigate the ability of three demensional-magnetic resonance elastography (3D-MRE) to establish a risk stratification system and perform tailored management for portal hypertension in cirrhosis or advanced chronic liver disease.",[310,311,312],"Cirrhosis, Liver","Portal Hypertension","Advanced Chronic Liver Disease",[290,292,314],"advanced chronic liver disease",{"date":295,"type":38},{"date":297,"type":38},{"date":196,"type":22},{"name":43,"class":44},{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":17,"minAge":325,"maxAge":326,"enrollmentInfo":327,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":4},"100617590","neuroendoscopic-surgery-with-ommaya-reservoir-implantation-vs-burr-hole-drainage-for-infantile-postmeningitis-subdural-lesions-superior-efficacy-critical-impact-of-surgical-timing-and-pathogenic-bacteria-as-risk-factors-for-progression-100617590","NCT07320599","Neuroendoscopic Surgery With Ommaya Reservoir Implantation vs. Burr Hole Drainage for Infantile Postmeningitis Subdural Lesions: Superior Efficacy, Critical Impact of Surgical Timing, and Pathogenic Bacteria as Risk Factors for Progression","Inclusion Criteria:\n\n\\- All enrolled children had received ≥3 weeks of standardized anti-infection therapy, including empirical or susceptibility-guided antibiotics administered intrathecal (post-lumbar puncture) or intravenous and dexamethasone administered intrathecal or intravenous. During conservative management, vital\u002Fneurological signs were closely monitored, with regular imaging to assess fluid thickness and empyema progression. Cranial ultrasound (primary modality, ≤3-day intervals) was performed, while CT\u002FMRI were conducted ≤weekly.\n\nExclusion Criteria:\n\n* subdural fluid collections secondary to viral meningitis; secondary collections with confirmed craniocerebral trauma history; diagnosed tuberculous subdural fluid collection; intracranial space-occupying lesions.","1 Month","1 Year",{"count":284,"type":22},"Globally, approximately 750,000 cases of infantile meningitis occur annually\\[1\\]. Clinical data show infantile postmeningitis subdural fluid collection (IPSFC) is the most common complication of infantile bacterial meningitis (IBM), with a progression rate of 30-60% (39% in standardized treatment cohorts)\\[2\\]. Pathogens, predominantly Escherichia coli and Streptococcus pneumoniae, account for 70% of IPSFC cases\\[3\\]. IPSFC progresses to subdural empyema (IPSE) in 3.7-17.6% of cases, with 87.1% of IPSE cases occurring in infants \\\u003C1 year old\\[4\\]. Collectively termed infantile postmeningitis subdural space lesions (IPSSL), these conditions impose the highest burden in Sub-Saharan Africa's \"Meningitis Belt\" and Southeast Asia\\[5\\]. IPSE progresses rapidly in infants, with a mortality rate of 18% and 50% of survivors developing neurological sequelae (e.g., epilepsy, motor\u002Fintellectual disability, sensory impairment)\\[6\\]. While spontaneously resolved IPSFC shows no significant sequelae, prolonged IPSE disrupts brain development, requires extended treatment, and incurs substantial familial burdens.\n\nCauses of IPSFC secondary to IBM include increased subdural capillary permeability (with plasma exudation), cerebrospinal fluid (CSF) circulation\u002Fabsorption disturbance, immature infantile blood-brain barrier (BBB), and underdeveloped arachnoid granulations\\[7\\]. IPSFC typically develops on days 7-10 of IBM and is staged by fluid thickness: Stage I (\\\u003C0.3 mm), Stage II (3-8 mm), Stage III (\\>8 mm)\\[8\\]. Uncontrolled IBM infection, due to inappropriate antibiotics, inadequate dosage, delayed treatment, or infantile immunocompromise, e.g., preterm infants, allows pathogens to invade and proliferate in the subdural space, inducing local secondary infection, inflammatory cell infiltration, and accumulation of pathogen metabolites\u002Fnecrotic tissue-ultimately progressing to IPSE\\[9\\]. Fibrinogen exudation and fibroblast activation may further form subdural fibrous cords, septa, purulent plaques, inflammatory pseudomembranes, and other fibro-inflammatory proliferative lesions (FIPLs)\\[10\\]. IPSE causes more severe mass\u002Ftoxic effects, requiring aggressive surgical intervention. Cranial MRI shows empyema cavity rim enhancement, heterogeneous internal signals due to fluid collection septa, and dural thickening.\n\nThe progression rate of IPSFC to IPSE ranges from 3.7% to 17.6%, influenced by IBM pathogen types, therapeutic intervention, and host immunity\\[11\\]. However, large-scale cohort studies on risk factors for this progression remain lacking. Early adequate antibiotic therapy reduces IPSFC incidence by nearly 50%, whereas delayed intervention may accelerate IPSFC onset (day 3-7) via unremitting meningeal permeability\\[12\\]. Inadequate antibiotic courses may promote persistent IPSFC progression with FIPLs formation. Some pediatric neurosurgeons advocate extending antibiotic therapy beyond 21 days for IPSFC to prevent progression to IPSE\\[13\\].\n\nDespite early antibiotic therapy reducing IBM mortality, IPSSL management remains challenging. A clinical study showed 22.4% of IPSFC cases required surgery, but occult inflammation in infants can prolong IPSFC up to 2 months\\[14\\]. Infantile unclosed fontanelles and cranial elasticity increase neurosurgical complication risks. Current consensus suggests asymptomatic\u002Fsmall-volume fluid collections (thickness \\\u003C5 mm) often resolve spontaneously, obviating intervention\\[15\\]. Ultrasound-guided subdural puncture (US-SP-AF) is the first-line invasive treatment, curing about 50% of infants acutely but with a 30-50% recurrence rate. Whether US-SP-AF reduces IPSFC-to-IPSE progression remains controversial. For US-SP-AF-resistant cases, minimally invasive burr hole irrigation (BHID) with silicone tube drainage (3-5 days) is used; BHID shows higher cure rates than US-SP-AF but still has a 20-33% recurrence rate in small cohorts\\[16\\].\n\nNeuroendoscopic technique allows rigid endoscope entry into the subdural space for visualized resection of pathological tissues, management of multiloculated cavities, adhesion lysis, and FIPLs irrigation. This approach directly targets the pathological substrate under vision, reducing residual lesions and recurrence rates compared to traditional methods. In adult cohorts, 6-month postoperative fluid collection recurrence rates are only 8% with neuroendoscopy, versus 33% with BHID\\[17\\]. However, neuroendoscopic exploration is technically demanding and equipment-dependent. The Ommaya reservoir offers advantages in postoperative management of cerebrospinal fluid-related disorders, including precise drainage, dynamic monitoring of disease progression, and local drug administration. However, it may be prone to catheter obstruction by pathological components\\[18\\].\n\nSevere IPSSL causes intracranial hypertension and neurodevelopmental impairment, requiring comprehensive pediatric neurosurgical and pharmacologic strategies. Treatment selection depends on IPSFC\u002FIPSE pathological features. Current stu",[330],"Meningitis",[332],"infantile meningitis","2025-12-25",{"date":335,"type":38},"2026-01-06",{"date":337,"type":22},"2026-03-01",{"date":339,"type":22},"2027-06-30",{"name":43,"class":44},{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":348,"targetDuration":4,"studyType":23,"phases":349,"briefSummary":350,"conditions":351,"keywords":352,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":45},"100515341","magnetic-resonance-elastography-in-glioma-exploring-tumor-stiffness-and-adhesion-100515341","NCT05990244","Magnetic Resonance Elastography in Glioma: Exploring Tumor Stiffness and Adhesion","Comprehensive Assessment of Tumor Stiffness and Adhesion in Glioma Using Magnetic Resonance Elastography: A Prospective Study","Inclusion Criteria:\n\n1. age older than 18 years\n2. Karnofsky performance status higher than 60\n3. with written informed consent\n4. MRE performed within one week before surgery\n5. tumor diameter \\> 2 cm\n\nExclusion Criteria:\n\n1. previous treatment for glioma\n2. inability to complete MRE due to intolerance (e.g., vibration-related discomfort or claustrophobia)\n3. completed MRE with suboptimal wave image quality (e.g., motion artifacts or inad-equate wave amplitude)\n4. failure to proceed with surgery after MRE\n5. missing IDH results",{"count":284,"type":22},[25],"this study will investigate the relationship between tumor stiffness and adhesion in gliomas using MRE. By utilizing preoperative MRE and Intraoperative neuronavigation, followed by comprehensive molecular pathology analysis, we aim to explore the correlation of tumor stiffness and adhesion with molecular and genetic characteristics of gliomas. Additionally, the predictive value of MRE in terms of pathological staging and prognosis will be determined. This research may pave the way for improved clinical decision-making, personalized treatment approaches, and more accurate clinical trials for glioma patients.",[238],[63,353,243,267,354],"Brain tumor","Tumor molecular pathology","2025-11-24",{"date":357,"type":38},"2025-12-02",{"date":359,"type":38},"2017-01-01",{"date":361,"type":22},"2027-07-01",{"name":43,"class":44},{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":282,"enrollmentInfo":370,"targetDuration":4,"studyType":23,"phases":372,"briefSummary":373,"conditions":374,"keywords":378,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":385,"leadSponsor":387,"locationsCount":45},"100601097","near-infrared-imaging-of-motor-imagery-effects-in-spinal-cord-injury-100601097","NCT07106060","Near-Infrared Imaging of Motor Imagery Effects in Spinal Cord Injury","A Near-Infrared Functional Imaging Study on Motor Imagery Training in Patients With Spinal Cord Injury","Inclusion Criteria:\n\n1. The vital signs are stable and the spine is stable, making the subject suitable for exercise testing.\n2. Patients with spinal cord injury (SCI) who meet the international diagnostic criteria for SCI neurology revised by the American SCI Society in 2019 and have been diagnosed by CT or MRI.\n3. The injury level of SCI is C5-T12, and the ASIA grade is A-C.\n4. The course of the disease is ≤12 months (but the spinal shock period must have passed).\n5. Age: 18-75 years old, regardless of gender.\n6. Good cognitive function, able to understand and actively participate in the training program, and willing to sign the informed consent form for this clinical study.\n\nExclusion Criteria:\n\n1. Those with tumors, tuberculosis, hematologic diseases, or dysfunction of important organs such as the heart and liver;\n2. Those with unstable fractures;\n3. Those with severe abnormal limb muscle tone and joint contracture deformities;\n4. Those with severe pain that cannot tolerate activities;\n5. Those with severe emotional problems who cannot cooperate to complete the study.",{"count":371,"type":22},36,[25],"The primary objective of this clinical trial is to investigate the efficacy of motor imagery-based brain-computer interface (MI-BCI) technology in improving motor function among patients with spinal cord injury (SCI), as well as its impact on cortical motor area function across varying states. To achieve this, the study will implement MI-BCI intervention in SCI patients, evaluate post-treatment motor function improvements, and assess changes in cortical motor area oxygen metabolism (via functional near-infrared spectroscopy, fNIRS) and neural activity (via electroencephalography, EEG). The ultimate goal is to establish a novel rehabilitation strategy for SCI.\n\nSpecifically, the trial aims to: (1) determine whether MI-BCI effectively enhances motor function in SCI patients; and (2) clarify the differential effects of MI-BCI on cortical motor area function under distinct states (e.g., resting vs. task-performing) in this population.\n\nParticipants will be randomly assigned to one of two groups: the experimental group will undergo MI-BCI training, while the control group will receive active cycling training (as a conventional rehabilitation control). Both interventions will be structured as 20-minute sessions, administered 5 days per week, over a total of 4 weeks.Pre- and post-treatment assessments will include: lower limb motor function (measured by the Lower Limb Motor Score), activities of daily living (evaluated via the Modified Barthel Index), walking capacity (quantified using the Spinal Cord Injury Walking Index), and cortical motor activity (captured through fNIRS and EEG measurements).",[375,376,377],"SCI - Spinal Cord Injury","Motor Imagery","Brain-Computer Interfaces",[375,379,377,380],"motor imagery","Functional near-infrared spectroscopy","2025-07-30",{"date":383,"type":38},"2025-08-06",{"date":194,"type":38},{"date":386,"type":22},"2026-02-01",{"name":43,"class":44},{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":81,"minAge":18,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":23,"phases":397,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":4},"100600755","phase-2-a-randomized-study-of-js004-and-toripalimab-combined-with-chemotherapy-vs-toripalimab-combined-with-chemotherapy-vs-chemotherapy-alone-as-neoadjuvant-therapy-for-stage-ii-iii-triple-negative-breast-cancer-tnbc-100600755","NCT07101614","A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).","An Open-label, Randomized, Multi-center, Multi-cohort Clinical Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).","Inclusion Criteria:\n\n1. Subjects must voluntarily participate in this study, sign the informed consent form, demonstrate good compliance, and cooperate with follow-up visits.\n2. Age ≥ 18 years.\n3. ECOG score ≤ 1.\n4. Newly diagnosed, non-metastatic breast cancer of stage II-III, confirmed by histopathology or cytopathology (T1c-2 cN1-2 (≥2cm) or T3-4 cN0-2).\n5. Pathologically confirmed hormone receptor-negative (ER and PR negative) and HER2-negative advanced breast cancer. In cases of multiple pathological results, the definition of triple-negative breast cancer is based on the final molecular subtype result from the last biopsy pathology. (ER negativity: immunohistochemical staining in \\\u003C1% of tumor cells; PR negativity: immunohistochemical staining in \\\u003C1% of tumor cells; HER2 negativity: immunohistochemical score of 0, 1+, or FISH\u002FCISH negative).\n6. Have at least one measurable lesion according to the RECIST v1.1 criteria.\n7. Functional levels of vital organs must meet the following requirements (without any corrective treatment with blood components or cytokine growth factors within 14 days before the first dose):\n\n   1. Bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL, hemoglobin ≥ 90 g\u002FL.\n   2. Liver and kidney function: Albumin level ≥ 3.0 g\u002FdL, total bilirubin ≤ 1.5 × upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN, alkaline phosphatase ≤ 2.5 × ULN, urea nitrogen and serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60 mL\u002Fmin (calculated according to the Cockcroft-Gault formula).\n   3. Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.\n   4. Echocardiography (ECHO) showing left ventricular ejection fraction (LVEF) ≥ 50%.\n   5. QTcF ≤ 470 msec.\n8. Within 7 days before the first dose, women of reproductive potential must have a negative serum pregnancy test and agree to use effective contraceptive measures during the study drug administration and for 6 months after the last dose. For this protocol, women of reproductive potential are defined as sexually mature women who: 1) have not undergone hysterectomy or bilateral oophorectomy, and 2) have not experienced spontaneous menstruation cessation for a continuous period of 24 months (amenorrhea following cancer treatment does not exclude fertility) (i.e., menstruation has occurred at any time within the previous 24 consecutive months). For male patients with female partners of reproductive potential, they must agree to use effective contraceptive measures during the study drug administration and for 6 months after the last dose.\n9. Voluntarily participate in this study, sign the informed consent form, demonstrate good compliance, and be willing to cooperate with visits and study-related procedures.\n\nExclusion Criteria:\n\n1. Prior exposure to drugs targeting the same therapeutic target as the study treatment drug planned for administration.\n2. Radiotherapy, chemotherapy, surgery, or other targeted immunotherapy for triple-negative breast cancer before enrollment.\n3. Uncontrolled central nervous system metastases (symptomatic or requiring glucocorticoids or mannitol for symptom control).\n4. Inflammatory breast cancer, bilateral breast cancer, or occult breast cancer.\n5. History of clinically significant or uncontrolled cardiac disease within 6 months before the first dose, including congestive heart failure, angina pectoris, myocardial infarction, or ventricular arrhythmias.\n6. Presence of severe concomitant diseases that, in the investigator's judgment, pose a significant risk to the patient's safety or ability to complete the study (including but not limited to severe hypertension not controlled by medication, severe diabetes, active infections, etc.).\n7. Malignancy within 5 years before the first dose (except for cured basal cell carcinoma of the skin and cervical carcinoma in situ).\n8. Active autoimmune diseases requiring systemic treatment within 2 years before the first dose, except for vitiligo, type 1 diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis requiring only hormone replacement therapy.\n9. Receipt of live or attenuated vaccines within 4 weeks before the first dose of the study drug.\n10. Known or suspected interstitial pneumonia. Presence of other moderate to severe respiratory diseases within 3 months before the first dose that may interfere with the detection or management of drug-related lung toxicity, including but not limited to idiopathic pulmonary fibrosis, organizing pneumonia\u002Fbronchiolitis obliterans, pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease (COPD), obstructive\u002Frestrictive lung diseases, etc.; as well as any autoimmune, connective tissue, or inflammatory diseases affecting the lungs, such as rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc., or prior total lung resection surgery.\n11. Known history of human immunodeficiency virus (HIV) infection.\n12. Known history of hepatitis B or active hepatitis C virus infection.\n13. Prior allergy to any component or excipient of the study drug planned for administration.\n14. Other conditions deemed unsuitable for participation in the study by the investigator.",{"count":396,"type":22},125,[398],"PHASE2","The objective of this study is to evaluate the efficacy and safety of chemotherapy plus toripalimab, with or without JS004,as neoadjuvant therapy for patients with triple-negative breast cancer (TNBC). TNBC patients were randomly assigned in a 2:2:1 ratio to receive either JS004 plus toripalimab plus chemotherapy, toripalimab plus chemotherapy, or chemotherapy alone.Surgery will be performed within 5 weeks after the last dose of neoadjuvant treatment.",[401],"TNBC - Triple-Negative Breast Cancer","2025-07-28",{"date":404,"type":38},"2025-08-03",{"date":406,"type":22},"2025-09-01",{"date":408,"type":22},"2028-11-30",{"name":43,"class":44},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":417,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":429,"locationsCount":45},"100596791","effect-of-threshold-pressure-loaded-rmt--ttbs-on-respiratory-function-in-sci-patients-100596791","NCT07050069","Effect of Threshold Pressure-Loaded RMT + tTBS on Respiratory Function in SCI Patients","The Effect of Threshold Pressure-loaded Respiratory Muscle Training Combined With Transcranial Intermittent Theta Burst Stimulation on Respiratory Function in Patients With Spinal Cord Injury","Inclusion Criteria:\n\n* Patients with spinal cord injury (SCI) meeting the 2019 revised International Standards for Neurological Classification of Spinal Cord Injury by the American Spinal Injury Association (ASIA), confirmed by CT\u002FMRI.\n* Aged 18-80 years.\n* Time since injury: 2 weeks to 6 months, with spinal shock resolved.\n* Injury level at T12 or above, ASIA Impairment Scale (AIS) grade A-C.\n* Patients providing written informed consent after study explanation.\n\nExclusion Criteria:\n\n* Patients with severe cardiorespiratory diseases (e.g., pneumothorax).\n* Unstable vital signs (e.g., hypotension, arrhythmia).\n* Cognitive\u002Fpsychiatric disorders precluding cooperation.\n* Requiring mechanical ventilation.\n* Congenital spinal\u002Flimb deformities.\n* Contraindications to magnetic stimulation: intracranial metal implants, pacemakers, etc.",{"count":418,"type":22},60,[25],"The purpose of this clinical trial is to understand whether threshold pressure load respiratory muscle training combined with iTBS can effectively improve the respiratory function of SCI patients. The main questions it aims to answer are:\n\n* The impact of threshold pressure load respiratory muscle training on the respiratory function of SCI patients.\n* The impact of iTBS treatment at the cortical projection point of the diaphragm on the respiratory function of SCI patients.\n* Whether the combination of the above two treatment techniques is superior to single treatment.",[422],"Spinal Cord Injuries","2025-07-02",{"date":425,"type":38},"2025-07-03",{"date":427,"type":38},"2024-12-25",{"date":333,"type":22},{"name":43,"class":44},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":282,"enrollmentInfo":437,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":438,"conditions":439,"keywords":441,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":451,"locationsCount":4},"100596288","study-on-dynamic-changes-of-serum-igf-1-post-cerebral-hemorrhage-and-its-prognostic-correlation-100596288","NCT07043504","Study on Dynamic Changes of Serum IGF-1 Post-Cerebral Hemorrhage and Its Prognostic Correlation","Study on the Dynamic Changes of Serum IGF-1 After Cerebral Hemorrhage and Its Correlation With Prognosis of Patients","Inclusion Criteria:\n\n1. Aged 18 to 75 years old;\n2. Patients with intracerebral hemorrhage (NIHSS ≥5 points);\n3. No history of cerebrovascular diseases with residual functional impairment before brain injury;\n4. Hospitalized within 72 hours after injury;\n5. BMI ≤28.\n\nExclusion Criteria:\n\n1. Patients with severe cardiac, hepatic, renal, or pulmonary dysfunction;\n2. Glycated hemoglobin \\>9.0% at screening;\n3. History of hypothalamic-pituitary related diseases or severe endocrine diseases;\n4. Use of drugs affecting endocrine function (such as glucocorticoids, growth hormones) within the past six months;\n5. Pregnant patients. -",{"count":284,"type":22},"The purpose of this study is to dynamically observe the dynamic changes of serum IGF-1 after intracerebral hemorrhage, explore the impact and correlation of serum IGF-1 with the severity of the patient's condition and prognosis, and provide a reference for clinical treatment timing.",[440],"Insulin-Like Growth Factor I",[442,443,444],"Intracerebral Hemorrhage","Prognosis","IGF-1","2025-06-21",{"date":447,"type":38},"2025-06-29",{"date":449,"type":22},"2025-07-01",{"date":153,"type":22},{"name":43,"class":44},{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":282,"enrollmentInfo":459,"targetDuration":4,"studyType":23,"phases":461,"briefSummary":462,"conditions":463,"keywords":464,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":45},"100594088","fnirs-driven-visual-feedback-training-to-restore-walking-after-stroke-100594088","NCT07014891","fNIRS-Driven Visual Feedback Training to Restore Walking After Stroke","A Study on Visual Feedback Motor Control Training Using Near-Infrared Spectroscopy (fNIRS) Brain Functional Imaging for Walking Function Recovery in Stroke Patients","Inclusion Criteria:\n\n* 1: Vital signs are stable, with no severe cardiopulmonary diseases, making the patient suitable for exercise testing.\n\n  2: All patients are diagnosed with stroke by head CT or MRI, with clinical manifestations of unilateral limb hemiplegia.\n\n  3: The Brunnstrom stage of the lower limb is 3-5, quadriceps muscle strength is ≥ grade 3, modified Ashworth scale for the lower limb is \\\u003C grade 2, and Hoffer walking scale is ≥ grade 2.\n\n  4: This is their first onset of the disease, with a disease course of ≤ 6 months, and the condition is stable.\n\n  5: Patients have no severe cognitive impairment or sensory aphasia, can understand and actively participate in the training program, and have provided informed consent by signing the consent form for this clinical study.\n\n  6: Age: 18-75 years old, no gender restrictions.\n\nExclusion Criteria:\n\n* 1: Patients with tumors, tuberculosis, hematological diseases, or functional impairments of vital organs such as the heart or liver.\n\n  2: Those with lower limb musculoskeletal disorders, such as knee arthritis or lower limb fractures.\n\n  3: Individuals with severe abnormal muscle tone in the limbs or joint contracture deformities.\n\n  4: Patients experiencing severe pain that prevents them from tolerating physical activity.\n\n  5: Special populations, such as individuals with mental illnesses, breastfeeding women, or pregnant women.",{"count":460,"type":22},44,[25],"The objective of this clinical trial is to investigate whether intelligent visual feedback-based lower limb motor control training is more effective than conventional rehabilitation training in promoting walking ability recovery among stroke patients with hemiplegia. The trial aims to address the primary question of the impact of intelligent visual feedback motor control training on the walking function of stroke patients with hemiplegia, and uses three-dimensional gait analysis for precise quantitative evaluation of therapeutic effects. Functional near-infrared spectroscopy (fNIRS) will be employed to explore patients' cerebral functional connectivity and cortical activation, and to analyze the correlation between fNIRS data and walking function scores (such as those from three-dimensional gait analysis), providing effective methods and a reliable reference basis for rehabilitation training of post-stroke hemiplegic patients.\n\nParticipants will be randomly divided into two groups: the experimental group receiving intelligent visual feedback motor control training, and the control group receiving Bobath ball training, 20 minutes per day, 5 days per week, for a total of four weeks. Before and after the treatment, indicators including fNIRS brain functional imaging, three-dimensional gait analysis, and Fugl-Meyer Assessment will be evaluated.",[28],[465,466,380,467],"stroke","visual feedback","walking ability","2025-06-18",{"date":470,"type":38},"2025-06-24",{"date":472,"type":38},"2024-12-15",{"date":474,"type":22},"2025-12-03",{"name":43,"class":44},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":483,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":485,"conditions":486,"keywords":488,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":45},"100532099","mre-for-assessment-of-histopathological-growth-patterns-in-colorectal-liver-metastases-100532099","NCT06208397","MRE for Assessment of Histopathological Growth Patterns in Colorectal Liver Metastases","Noninvasive Evaluation in Diagnosis and Treatment of Histopathological Growth Patterns in Colorectal Liver Metastases Using MR Elastography-based Shear Strain Mapping","Inclusion Criteria:\n\n* Diagnosed CRLM\n* Pathologic results obtained in surgical patients\n* No contraindications for magnetic resonance imaging examination\n\nExclusion Criteria:\n\n* Image quality does not meet the measurement requirements.\n* the diameter of CRLM \\\u003C1cm\n* Combined with other important organ dysfunction\n* Combined with malignant tumor\n* Patients who do not sign an informed consent\n* Patients with metallic implants or foreign bodies in their bodies (pacemakers, artificial metallic heart valves, metal joints, metal implants, and those who cannot remove dentures, insulin pumps, or contraceptive rings)",{"count":484,"type":22},50,"The goal of this study is to investigate the value of MR elastography-based SII as a means of detecting HGP noninvasively in patients with pathology-proven CRLM. MRE will provide a direct measure of tumor-liver adhesion to investigate the relationship between imaging findings and pathophysiological changes in the Liver.",[487],"Metastatic Colorectal Cancer",[489,62,63,490],"colorectal cancer liver metastasis","Histopathological growth patterns","2025-05-14",{"date":493,"type":38},"2025-05-15",{"date":495,"type":38},"2023-12-24",{"date":497,"type":22},"2026-12-24",{"name":43,"class":44},{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":282,"enrollmentInfo":505,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":515,"locationsCount":45},"100551690","multi-parametric-magnetic-resonance-imaging-for-the-precise-diagnosis-and-quantitative-study-of-liver-steatosis-inflammation-and-fibrosis-in-chronic-liver-disease-100551690","NCT06463366","Multi-parametric Magnetic Resonance Imaging for the Precise Diagnosis and Quantitative Study of Liver Steatosis, Inflammation, and Fibrosis in Chronic Liver Disease.","Inclusion Criteria:\n\n1. Chronic liver disease (including viral hepatitis, alcoholic hepatitis, non alcoholic steatohepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, etc..)\n2. Age range of 18 to 75 years old\n3. Accept systematic antiviral therapy or hormone or ursodesoxycholic acid or supportive liver protection therapy\n\nExclusion Criteria:\n\n1. Age less than 18 years\n2. Unable or unwilling to give informed consent\n3. Contra-indications to MRI\n4. Electrical implants such as cardiac pacemakers or perfusion pumps\n5. Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants\n6. Ferromagnetic objects such as jewelry or metal clips in clothing\n7. Pregnant subjects\n8. Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions",{"count":284,"type":22},"To construct a novel, non-invasive, accurate, and convenient method to achieve the degree of liver damage is an important general problem in the management of patients with chronic liver disease. The investigators would like to develop non invasive advanced Magnetic Resonance Imaging (MRI) techniques (MR elastography, MRI-PDFF) to assess the degree of liver damage in patients with chronic liver disease. These techniques could reach high diagnostic performance for detection of liver fibrosis, inflammation and liver fat content; and could decrease the number of liver biopsies, which have risks and sample only a small portion of the liver.",[508],"Liver Stiffness","2025-02-26",{"date":511,"type":38},"2025-02-28",{"date":513,"type":38},"2022-06-14",{"date":406,"type":22},{"name":43,"class":44},{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":81,"minAge":18,"maxAge":282,"enrollmentInfo":523,"targetDuration":4,"studyType":23,"phases":525,"briefSummary":526,"conditions":527,"keywords":529,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":45},"100542235","phase-2-shr-a1811-alone-or-in-combination-with-adebrelimab-as-neoadjuvant-treatment-in-hr-positiveher2-low-breast-cancer-100542235","NCT06340230","SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive\u002FHER2 Low Breast Cancer","A Phase II Study of SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive\u002FHER2 Low Breast Cancer","Inclusion Criteria:\n\n1. Female patients aged ≥ 18 but ≤ 75 years\n2. Histologically confirmed to be HR+\u002FHER2-Low invasive breast cancer\n3. Treatment-naive patients with stage II-III\n4. Eastern Cooperative Oncology Group (ECOG) score is 0 or 1\n5. Good level of organ function\n6. Subjects must participate voluntarily, sign the informed consent form, have good compliance, and cooperate with follow-up visits\n\nExclusion Criteria:\n\n1. Previously been treated with any anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.)\n2. Received any other anti-tumor therapy at the same time\n3. Bilateral breast cancer, inflammatory breast cancer or occult breast cancer\n4. Stage IV breast cancer\n5. Not confirmed by histopathology\n6. With a history of any malignancies in the past 5 years, excluding cured cervical carcinoma in situ and melanoma skin cancer\n7. Participated in other drug clinical trials within 4 weeks before enrollment\n8. Known allergic history of the drug components of this protocol\n9. History of immunodeficiency\n10. Clinically significant cardiovascular diseases\n11. Known or suspected interstitial lung disease\n12. Active hepatitis and liver cirrhosis\n13. Known hereditary or acquired bleeding thrombotic tendency\n14. History of neurological or psychiatric disorders",{"count":524,"type":22},93,[398],"This is an open-label, phase II study evaluating the efficacy and safety of SHR-A1811 alone or in combination with Adebrelimab in Stage II-III HR Positive\u002FHER2 Low Breast Cancer. Subjects will receive the neoadjuvant therapy of SHR-A1811 alone or in combination with Adebrelimab for six cycles, and then undergo surgery within 4 weeks after neoadjuvant therapy. Efficacy will be assessed every 2 cycles.",[528],"HR Positive\u002FHER2 Low Breast Cancer",[530,531,532,528],"SHR-A1811","Adebrelimab","Neoadjuvant","2024-12-02",{"date":535,"type":38},"2024-12-04",{"date":537,"type":38},"2024-08-23",{"date":539,"type":22},"2031-02-28",{"name":43,"class":44},{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":53,"sex":81,"minAge":18,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":549,"conditions":550,"keywords":551,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":45},"100569779","the-association-between-plasma-metabolites-and-the-risk-efficacy-and-prognosis-in-early-breast-cancer-100569779","NCT06698679","The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer","Inclusion Criteria:\n\n* Cohort 1 Control Group: women without breast cancer or other malignancies. Case Group: patients with histologically confirmed carcinoma in situ or invasive breast cancer; no prior treatment; no distant metastasis; and not associated with other malignant tumor diseases.\n* Cohort 2 Pathologically diagnosed as breast cancer; Treatment niave patients; To receive standard neoadjuvant therapy; Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) .\n* Cohort 3 Patients who have been discharged after breast cancer treatment.\n\nExclusion Criteria:\n\n* Histologically undiagnosed breast cancer. Breast cancer with distant metastases. Combined with other malignant tumors. Participants must not have participated in other clinical trials within the past month, unless those trials are observational or non-interventional in nature.",{"count":548,"type":22},1000,"This study investigates plasma metabolites to clarify the relationship between these metabolites and breast cancer, aiming to identify valuable biomarkers. Furthermore, by incorporating clinical information-such as cancer stage, type, treatment outcomes, and prognosis-into prospective studies, the research seeks to further examine the correlation between plasma metabolites, treatment efficacy, and prognosis.",[89],[552,553],"metabolites","breast cancer","2024-11-19",{"date":556,"type":38},"2024-11-21",{"date":558,"type":22},"2024-11-15",{"date":560,"type":22},"2031-10-31",{"name":43,"class":44},{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":81,"minAge":18,"maxAge":4,"enrollmentInfo":568,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":570,"conditions":571,"keywords":572,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":576,"completionDateStruct":577,"leadSponsor":578,"locationsCount":45},"100569161","the-association-of-psychological-stress-with-the-efficacy-of-neoadjuvant-therapy-in-breast-cancer-100569161","NCT06690645","The Association of Psychological Stress with the Efficacy of Neoadjuvant Therapy in Breast Cancer","Inclusion Criteria:\n\n* 1.Age ≥ 18 years; 2.Histological and\u002For cytological diagnosis of breast cancer; 3.Treatment niave patients; 4.To receive standard neoadjuvant therapy; 5.Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; 6.Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) ; 7.Informed and agreed to participate in the study;\n\nExclusion Criteria:\n\n* 1\\. Breast cancer has not been confirmed through histological or cytological examinations.\n\n  2.Other breast cancer conditions that do not receive neoadjuvant therapy. 3.Combined with other malignant tumors. 4.Concurrent acute or chronic psychiatric disorders, along with having received antidepressant or anti-anxiety therapy within the past month.\n\n  5.Participants must not have engaged in any other clinical trials in the past month, unless those trials are observational or non-interventional in nature.",{"count":569,"type":22},840,"This study aims to explore the relationship between psychological stress and the therapeutic response in breast cancer patients who have received standard neoadjuvant chemotherapy.",[89],[573],"psychological stress, breast cancer","2024-11-13",{"date":558,"type":38},{"date":558,"type":22},{"date":153,"type":22},{"name":43,"class":44},{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":4,"eligibilityCriteria":585,"healthyVolunteers":12,"sex":17,"minAge":586,"maxAge":587,"enrollmentInfo":588,"targetDuration":589,"studyType":57,"phases":4,"briefSummary":590,"conditions":591,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":45},"100559963","a-clinical-study-of-hyperthyroidism-in-children-100559963","NCT06570967","A Clinical Study of Hyperthyroidism in Children","A Retrospective and Prospective Observational Study of Hyperthyroidism in Children","Inclusion Criteria:\n\n1. Age ≤14 years old\n2. Initial diagnosis of hyperthyroidism\n\nExclusion Criteria:\n\n1. Hyperthyroidism had been treated with medication in other hospitals,\n2. History of autoimmune hepatitis, viral hepatitis, hematological diseases, bone marrow or liver transplantation,\n3. Patients with incomplete clinical data","29 Days","14 Years",{"count":548,"type":22},"10 Years","This study intends to conduct a retrospective and prospective study on children with hyperthyroidism, and it is a non-intervention study to collect information on diagnosis and treatment and long-term follow-up of children with hyperthyroidism. To investigate the clinical characteristics, treatment effect, side effects and remission of hyperthyroidism in children, to analyze the predictive factors for the effect of antithyroid drug treatment, remission and recurrence after drug withdrawal, and to explore the risk factors related to the occurrence of antithyroid drug-related adverse reactions.",[592],"Hyperthyroidism","2024-08-24",{"date":595,"type":38},"2024-08-27",{"date":597,"type":38},"2023-07-18",{"date":599,"type":22},"2027-12",{"name":43,"class":44},""]